Mark D. Chatfield

7.8k citations
212 papers · 5.7k · 1 hit paper · h-index 42

Impact in

Papers in

  • Epidemiology 34
    • Pneumonia and Respiratory Infections 13
    • Respiratory viral infections research 8
    • Burkholderia infections and melioidosis 7
  • Psychiatry and Mental health 19
    • Cerebral Palsy and Movement Disorders 12
Co-authors
Carol Brayne (9 shared papers)Fiona E. Matthews (9 shared papers)Adrian Mander (2 shared papers)Peter Stanley Morris (17 shared papers)Anne B. Chang (27 shared papers)Steven Y. C. Tong (6 shared papers)Ross M Andrews (11 shared papers)Susan Ann Jebb (6 shared papers)
Journals
Developmental Medicine & Child Neurology (8 papers)BMJ Open (7 papers)Clinical Infectious Diseases (7 papers)BMC Public Health (5 papers)PLoS ONE (5 papers)
Partner nations
AustraliaUnited KingdomUnited States

In The Last Decade

Mark D. Chatfield

204 papers receiving 5.6k citations

Mark D. Chatfield's Hit Papers

Rapid Diagnostic Tests and Antimicrobial Stewardship Programs for the Management of Bloodstream Infection: What Is Their Relative Contribution to Improving Clinical Outcomes? A Systematic Review and Network Meta-analysis 2024 · 71 citations
710+1Years since publication204060
What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

  1. 2024 Clinical Infectious Diseases

Peers

Mark D. Chatfield
Comparison fields: 5 of 193
  • Applied Microbiology and Biotechnology 133
  • Otorhinolaryngology 230
  • Molecular Medicine 258
  • Clinical Biochemistry 209
  • Infectious Diseases 555
Replace Oyewole Christopher Durojaiye with:
Oyewole Christopher Durojaiye United Kingdom
Kosala Weerakoon Sri Lanka
Miglas Welay Gebregergis United States
Fathiah Zakham Morocco
Parham Habibzadeh Iran
Aravind P. Gandhi India
Emmanuel Edwar Siddig Sudan
Pirouz Naghavi United States
Ryenchindorj Erkhembayar United States
Ali Gholamrezanezhad United States
Mark D. Chatfield relative to Oyewole Christopher Durojaiye United Kingdom Oyewole Christopher Durojaiye's profile →
Citations per field
00.5×20×40×66×
Oyewole Christopher Durojaiye · 1×
Citations per year

Countries citing papers authored by Mark D. Chatfield

Since Specialization
Citations

This map shows the geographic impact of Mark D. Chatfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Chatfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Chatfield more than expected).

Fields of papers citing papers by Mark D. Chatfield

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark D. Chatfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Chatfield. The network helps show where Mark D. Chatfield may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark D. Chatfield, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark D. Chatfield Line = papers co-authored together Mark D. Chatfield links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 212 papers — load more, or switch the sort, to bring in the rest.

#Work
1
A systematic literature review of attrition between waves in longitudinal studies in the elderly shows a consistent pattern of dropout between differing studies
Journal of Clinical Epidemiology ·Mark D. Chatfield, Carol Brayne, Fiona E. Matthews
2005362
2
Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia
JAMA ·Steven Y. C. Tong, David Chien Lye, Dafna Yahav, Archana Sud, James Owen Robinson, Jane Nelson, Sophia Archuleta, Matthew A. Roberts
2020210
3
Markers of cardiovascular risk are not changed by increased whole-grain intake: the WHOLEheart study, a randomised, controlled dietary intervention
British Journal Of Nutrition ·Iain A. Brownlee, Carmel S. Moore, Mark D. Chatfield, David P. Richardson, P. Ashby, Sharron A. Kuznesof, Susan Ann Jebb, Chris J. Seal
2010177
4
Effect of changing the amount and type of fat and carbohydrate on insulin sensitivity and cardiovascular risk: the RISCK (Reading, Imperial, Surrey, Cambridge, and Kings) trial
American Journal of Clinical Nutrition ·Susan Ann Jebb, Julie Anne Lovegrove, Bruce A. Griffin, Gary Steven Frost, Carmel S. Moore, Mark D. Chatfield, Les J. C. Bluck, Christine M. Williams
2010161
5
Attrition and bias in the MRC cognitive function and ageing study: an epidemiological investigation
BMC Public Health ·Fiona E. Matthews, Mark D. Chatfield, Carol Freeman, Cherie McCracken, Carol Brayne, MRC CFAS
2004133
6
Bone mass and geometry of the tibia and the radius of master sprinters, middle and long distance runners, race-walkers and sedentary control participants: A pQCT study
Bone ·Désirée C. Wilks, Keith L. Winwood, Sally F. Gilliver, A. Kwiet, Mark D. Chatfield, Ingo Michaelis, Lin Sun, José Luis Ferretti
2009127
7
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study
Clinical Infectious Diseases ·Andrew Henderson, David L. Paterson, Mark D. Chatfield, Paul Anantharajah Tambyah, David Chien Lye, Partha Pratim De, R.T.P. Lin, Ka Lip Chew
2020125
8
L-arginine and Vitamin D Adjunctive Therapies in Pulmonary Tuberculosis: A Randomised, Double-Blind, Placebo-Controlled Trial
PLoS ONE ·Anna P. Ralph, Govert Waramori, Gysje J. Pontororing, Enny Kenangalem, Andri Wiguna, Emiliana Tjitra, Sandjaja, Dina Bisara Lolong
2013124
9
The Skillings–Mack Test (Friedman Test when There are Missing Data)
The Stata Journal Promoting communications on statistics and Stata ·Mark D. Chatfield, Adrian Mander
2009119
10
Impact of an Ivermectin Mass Drug Administration on Scabies Prevalence in a Remote Australian Aboriginal Community
PLoS neglected tropical diseases ·Thérèse Kearns, Rick Speare, Allen C. Cheng, James S. McCarthy, Jonathan Rhys Carapetis, Deborah C. Holt, Bart J. Currie, Wendy A. Page
2015112
11
Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial
The Lancet ·Asha Bowen, Steven Y. C. Tong, Ross M Andrews, Irene O’Meara, MALCOLM I. McDONALD, Mark D. Chatfield, Bart J. Currie, Jonathan Rhys Carapetis
2014104
12
The microbiology of impetigo in Indigenous children: associations between Streptococcus pyogenes, Staphylococcus aureus,scabies, and nasal carriage
BMC Infectious Diseases ·Asha Bowen, Steven Y. C. Tong, Mark D. Chatfield, Jonathan Rhys Carapetis
201497
13
Community-level socio-economic status and cognitive and functional impairment in the older population
European Journal of Public Health ·Nicole E. Basta, Fiona E. Matthews, Mark D. Chatfield, Carol Brayne +1 other
200794
14
The Skillings–Mack test (Friedman test when there are missing data)
PubMed ·Mark D. Chatfield, Adrian Mander +2 others
200990
15
Effect of a price discount and consumer education strategy on food and beverage purchases in remote Indigenous Australia: a stepped-wedge randomised controlled trial
The Lancet Public Health ·Julie Kay Brimblecombe, Megan Ferguson, Mark D. Chatfield, Selma Liberato, Anthony Gunther, Kylie Ball, Marjory Moodie, Edward W. Miles
201787
16
The effectiveness of telemedicine interventions to address maternal depression: A systematic review and meta-analysis
Journal of Telemedicine and Telecare ·Uthara Nair, Nigel R Armfield, Mark D. Chatfield, Sisira Edirippulige
201879
17
Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy
Journal of Thoracic Oncology ·Steven Chuan-Hao Kao, Sonja Klebe, Douglas W. Henderson, Glen Reid, Mark D. Chatfield, Nicola Jane Armstrong, Tristan D. Yan, Janette L. Vardy
201179
18
Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial
PLoS Medicine ·Tesfay Abreha, Jimee Hwang, Kamala Thriemer, Yehualashet Tadesse, Samuel Mesfin Girma, Zenebe Melaku, Ashenafi Assef, Moges Kassa
201779
19
General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines
International Journal of Pediatric Otorhinolaryngology ·Amanda Jane Leach, Christine Wigger, Jemima Beissbarth, Donna Woltring, Ross M Andrews, Mark D. Chatfield, Heidi Smith‐Vaughan, Peter Stanley Morris
201679
20
High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy
British Journal of Urology ·Richard Savdie, Lisa Glen Horvath, Ruth Pe Benito, Krishan Rasiah, Anne‐Maree Haynes, Mark D. Chatfield, Phillip D. Stricker, Jennifer Turner
201177

About Mark D. Chatfield

Mark D. Chatfield is a scholar working on Epidemiology, Psychiatry and Mental health, Infectious Diseases, Pharmacology and Otorhinolaryngology, having authored 212 papers that have together received 5.7k indexed citations. Recurring topics across this work include Pneumonia and Respiratory Infections (13 papers), Cerebral Palsy and Movement Disorders (12 papers), Antibiotics Pharmacokinetics and Efficacy (10 papers), Antimicrobial Resistance in Staphylococcus (9 papers), Respiratory viral infections research (8 papers), Cystic Fibrosis Research Advances (8 papers), Burkholderia infections and melioidosis (7 papers) and Antibiotic Resistance in Bacteria (7 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (133 citations), Otorhinolaryngology (230 citations), Molecular Medicine (258 citations), Clinical Biochemistry (209 citations) and Infectious Diseases (555 citations). Mark D. Chatfield has collaborated with scholars based in Australia, United Kingdom and United States. Frequent co-authors include Carol Brayne, Fiona E. Matthews, Adrian Mander, Peter Stanley Morris, Anne B. Chang, Steven Y. C. Tong, Ross M Andrews, Susan Ann Jebb, Jonathan Rhys Carapetis and Amanda Jane Leach. Their work appears in journals such as Developmental Medicine & Child Neurology, BMJ Open, Clinical Infectious Diseases, BMC Public Health and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oyewole Christopher DurojaiyeBreakdown of academic impact, for papers by Kosala WeerakoonBreakdown of academic impact, for papers by Miglas Welay GebregergisBreakdown of academic impact, for papers by Fathiah ZakhamBreakdown of academic impact, for papers by Parham HabibzadehBreakdown of academic impact, for papers by Aravind P. GandhiBreakdown of academic impact, for papers by Emmanuel Edwar SiddigBreakdown of academic impact, for papers by Pirouz NaghaviBreakdown of academic impact, for papers by Ryenchindorj ErkhembayarBreakdown of academic impact, for papers by Ali Gholamrezanezhad